drugset / Trial / NCT02712008
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).
Timeline
- Start
- 2016-03-02
- Primary completion
- 2017-07-10
- Completion
- 2017-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | nesvacumab | Monoclonal antibody | 3 mg | Intravitreal |
| Subject | nesvacumab | Monoclonal antibody | 6 mg | Intravitreal |